Alnylam Pharmaceuticals
Alnylam Pharmaceuticals
ALNY
NASDAQ
239.83
USD
0.46%
About
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells.
Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures.
It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 1.1M |
| Three Month Average Volume | 25.2M |
| High Low | |
| Fifty-Two Week High | 287.5499 USD |
| Fifty-Two Week Low | 141.975 USD |
| Fifty-Two Week High Date | 29 Aug 2024 |
| Fifty-Two Week Low Date | 25 Apr 2024 |
| Price and Volume | |
| Current Price | 262.69 USD |
| Beta | 0 |
| Relative Price Change | |
| Four Week Relative Price Change | -8.60% |
| Thirteen Week Relative Price Change | 65.36% |
| Twenty-Six Week Relative Price Change | 56.55% |
| Fifty-Two Week Relative Price Change | 5.97% |
| Year-to-Date Relative Price Change | 15.89% |
| Price Change | |
| One Day Price Change | -8.47% |
| Thirteen Week Price Change | 76.98% |
| Twenty-Six Week Price Change | 72.13% |
| Five Day Price Change | -3.65% |
| Fifty-Two Week Price Change | 32.79% |
| Year-to-Date Price Change | 37.24% |
| Month-to-Date Price Change | 10.62% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | -1.75401 USD |
| Book Value Per Share (Most Recent Quarter) | -0.02396 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -1.75401 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.02396 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | 1.23941 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 14.63734 USD |
| Revenue Per Share (Trailing Twelve Months) | 18.39359 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -3.52459 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.62848 USD |
| Normalized (Last Fiscal Year) | -3.52459 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -3.52459 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.57352 USD |
| Including Extraordinary Items (Last Fiscal Year) | -3.52459 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.62848 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 19.39188 USD |
| Cash Per Share (Most Recent Quarter) | 20.50171 USD |
| Cash Flow Per Share (Last Fiscal Year) | -3.09183 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.13817 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | 2.50175 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -54 |
| Cash Flow Revenue (Trailing Twelve Months) | 14 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -2.63% |
| Pretax Margin (Last Fiscal Year) | -23.71% |
| Pretax Margin (5 Year) | -93.92% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 83.02% |
| Gross Margin (Trailing Twelve Months) | 87.00% |
| Gross Margin (5 Year) | 83.66% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -15.43% |
| Operating Margin (Trailing Twelve Months) | 4.38% |
| Operating Margin (5 Year) | -81.86% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -24.08% |
| Net Profit Margin (Trailing Twelve Months) | -3.11% |
| Net Profit Margin (5 Year) | -94.26% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 107.00% |
| Revenue Growth (3 Year) | 89.45% |
| Revenue Change (Trailing Twelve Months) | 89.46% |
| Revenue Per Share Growth | 81.43% |
| Revenue Growth (5 Year) | 54.80% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -13.29% |
| Total Debt (5 Year) | 102.47% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 93.98% |
| EPS Change (Trailing Twelve Months) | 92.71% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | 804 |
| Price to Free Cash Per Share (Trailing Twelve Months) | 106 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -1,601,961,000 |
| Net Debt (Last Fiscal Year) | -1,418,606,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 18 |
| Price to Sales (Trailing Twelve Months) | 14 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | -100,000 |
| Price to Book (Most Recent Quarter) | -100,000 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | -100,000 |
| Long Term Debt to Equity (Most Recent Quarter) | -100,000 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 3 |
| Quick Ratio (Most Recent Quarter) | 3 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 3 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | 41.9M |
| Free Cash Flow (Trailing Twelve Months) | 318.9M |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -2 |
| Net Interest Coverage (Trailing Twelve Months) | 1 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | -100,000 |
| Total Debt to Equity (Most Recent Quarter) | -100,000 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -11.94% |
| Return on Assets (Trailing Twelve Months) | -1.97% |
| Return on Assets (5 Year) | -26.56% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -99,999.99% |
| Return on Equity (Trailing Twelve Months) | -99,999.99% |
| Return on Equity (5 Year) | -121.69% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -15.61% |
| Return on Investment (Trailing Twelve Months) | -2.62% |
| Return on Investment (5 Year) | -32.77% |